Table of Contents
To view the fulltext, log-in or choose pay-per-view options:
Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease
Allain H. ·
Destée A. ·
Petit H. ·
Patay M. ·
Schück S. ·
Bentué-Ferrer D. ·
Le Cavorzin P.
Eur Neurol 2000;44:22–30 (DOI: 10.1159/000008188)
The value of an early initial coadministration of levodopa (L-dopa) and lisuride in Parkinson’s disease was the main goal of the present study. Eighty-two patients with recently diagnosed idiopathic Parkinson’s disease were randomized into two groups for treatment with L-dopa alone or L-dopa + lisuride. The trial was double-blinded for the first year and open for the following 4 years. Selegiline (10 mg/day b.i.d.) was added in both groups at the end of the first year. Outcome measures were evolution of L-dopa dosage and Unified Parkinson’s Disease Rating Scale scores and subscores, and incidence of motor complications. The dropout rate was higher in the L-dopa group (63.4%) than in the combination group. Motor improvement was better (p < 0.01) in the L-dopa + lisuride group. Expected motor complications were rare, moderate and equivalent in the two groups despite a difference in L-dopa dosage (446.7 vs. 387.5 mg/day). Long-term follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups.
Copyright © 2000 S. Karger AG, Basel
||This item at the regular price: USD 38.00
|Payment from account
||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50